NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn’s disease: A preliminary report.

Barreiro-de Acosta M, Ouburg S, Morre SA, Crusius JBA,Lorenzo A, Potel J, Pena AS, Enrique Dominguez-Munoz J.

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn’s disease: A preliminary report.

Rev Esp Enferm Digest 2010; 102(10):591-5.
18_2010reed2010barreiroDescarga
  • Meibergdreef, 9
    1105 AZ Amsterdam
  • s.ouburg@amsterdamumc.nl
  • roelheijmans@gmail.com
  • pena.as@gmail.com
  • samorretravel@yahoo.co.uk

Web Design by unionn.es